Performance of ARWR Arrowhead Pharmaceuticals | -33.6% in 12m
Compare ARWR with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare Arrowhead Pharmaceuticals with its related Sector/Index XBI
Performance Duell ARWR vs XBI
| TimeFrame | ARWR | XBI |
|---|---|---|
| 1 Day | -0.16% | -0.02% |
| 1 Week | 1.13% | 4.06% |
| 1 Month | 5.62% | 8.15% |
| 3 Months | -15.2% | -0.60% |
| 6 Months | -4.07% | 32.05% |
| 12 Months | -33.6% | 8.91% |
| YTD | -19.4% | 2.62% |
| Rel. Perf. 1m | -0.23 | |
| Rel. Perf. 3m | -2.82 | |
| Rel. Perf. 6m | -3.81 | |
| Rel. Perf. 12m | -5.09 |
Is Arrowhead Pharmaceuticals a good stock to buy?
No, based on ValueRay Fundamental Analyses, Arrowhead Pharmaceuticals (NASDAQ:ARWR) is currently (May 2024)
a stock to sell. It has a ValueRay Fundamental Rating of -85.03 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ARWR as of May 2024 is 21.48. This means that ARWR is currently overvalued and has a potential downside of -14.08% (Sold with Premium).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ARWR as of May 2024 is 21.48. This means that ARWR is currently overvalued and has a potential downside of -14.08% (Sold with Premium).
Is ARWR a buy, sell or hold?
- Strong Buy: 7
- Buy: 3
- Hold: 4
- Sell: 0
- Strong Sell: 0
Values above 0%: ARWR is performing better - Values below 0%: ARWR is underperforming
Compare ARWR with Broad Market Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | -0.51% | 0.62% | -22.34% | -64.32% |
| US NASDAQ 100 | QQQ | -1.36% | 0.78% | -21.63% | -72.66% |
| US Dow Jones Industrial 30 | DIA | -0.19% | -0.11% | -19.19% | -56.76% |
| German DAX 40 | DBXD | 0.96% | 0.44% | -22.27% | -50.87% |
| UK FTSE 100 | ISFU | -0.93% | -4.86% | -22.27% | -48.28% |
| Shanghai Shenzhen CSI 300 | CSI 300 | 2.12% | 1.03% | -6.92% | -23.73% |
| Hongkong Hang Seng | HSI | -3.38% | -15.99% | -8.30% | -26.09% |
| Japan Nikkei 225 | EXX7 | 0.52% | 7.45% | -17.06% | -47.24% |
| India NIFTY 50 | INDA | -0.73% | 2.92% | -20.86% | -61.04% |
| Brasil Bovespa | EWZ | 1.60% | 0.23% | -1.56% | -47.33% |
ARWR Arrowhead Pharmaceuticals vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | 0.15% | 2.57% | -22.36% | -72.50% |
| Consumer Discretionary | XLY | 1.84% | 2.95% | -11.58% | -55.12% |
| Consumer Staples | XLP | -0.45% | -1.62% | -18.44% | -39.37% |
| Energy | XLE | 1.87% | 6.41% | -18.98% | -59.44% |
| Financial | XLF | -0.09% | -0.92% | -26.23% | -68.33% |
| Health Care | XLV | -0.78% | 0.32% | -18.62% | -47.01% |
| Industrial | XLI | 1.45% | 2.79% | -24.39% | -63.97% |
| Materials | XLB | 1.52% | 2.73% | -19.32% | -53.96% |
| Real Estate | XLRE | -1.00% | -1.96% | -13.59% | -45.00% |
| Technology | XLK | -2.54% | 0.40% | -20.41% | -74.05% |
| Utilities | XLU | -0.19% | -9.53% | -22.49% | -45.76% |
| Aerospace & Defense | XAR | 0.73% | -1.91% | -19.98% | -60.53% |
| Biotech | XBI | -2.93% | -2.53% | -36.12% | -42.49% |
| Homebuilder | XHB | 1.66% | 0.24% | -35.79% | -86.63% |
| Retail | XRT | -1.24% | -2.21% | -29.25% | -63.30% |
Does Arrowhead Pharmaceuticals outperform its market, is ARWR a Sector Leader?
No, over the last 12 months Arrowhead Pharmaceuticals (ARWR) made -33.58%, while its related Sector, the SPDR S&P Biotech (XBI) made 8.91%.
Over the last 3 months ARWR made -15.20%, while XBI made -0.60%.
No, over the last 12 months Arrowhead Pharmaceuticals (ARWR) made -33.58%, while its related Sector, the SPDR S&P Biotech (XBI) made 8.91%.
Over the last 3 months ARWR made -15.20%, while XBI made -0.60%.
| Period | ARWR | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 5.62% | 8.15% | 5.00% |
| 3 Months | -15.20% | -0.60% | 6.17% |
| 12 Months | -33.58% | 8.91% | 30.74% |